- Home
- IKT vs ENX Comparison
IKT vs ENX Comparison
Compare IKT & ENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- ENX
- Stock Information
- Founded
- IKT 2008
- ENX 2002
- Country
- IKT United States
- ENX United States
- Employees
- IKT N/A
- ENX N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- ENX Finance/Investors Services
- Sector
- IKT Health Care
- ENX Finance
- Exchange
- IKT Nasdaq
- ENX Nasdaq
- Market Cap
- IKT 167.2M
- ENX 174.2M
- IPO Year
- IKT 2020
- ENX N/A
- Fundamental
- Price
- IKT $1.90
- ENX $9.24
- Analyst Decision
- IKT Buy
- ENX
- Analyst Count
- IKT 2
- ENX 0
- Target Price
- IKT $8.00
- ENX N/A
- AVG Volume (30 Days)
- IKT 147.0K
- ENX 25.4K
- Earning Date
- IKT 05-14-2025
- ENX 01-01-0001
- Dividend Yield
- IKT N/A
- ENX 3.94%
- EPS Growth
- IKT N/A
- ENX N/A
- EPS
- IKT N/A
- ENX 0.16
- Revenue
- IKT N/A
- ENX N/A
- Revenue This Year
- IKT N/A
- ENX N/A
- Revenue Next Year
- IKT N/A
- ENX N/A
- P/E Ratio
- IKT N/A
- ENX $61.00
- Revenue Growth
- IKT N/A
- ENX N/A
- 52 Week Low
- IKT $1.12
- ENX $7.84
- 52 Week High
- IKT $4.20
- ENX $10.07
- Technical
- Relative Strength Index (RSI)
- IKT 42.84
- ENX 42.85
- Support Level
- IKT $1.58
- ENX $8.74
- Resistance Level
- IKT $2.22
- ENX $9.72
- Average True Range (ATR)
- IKT 0.22
- ENX 0.21
- MACD
- IKT 0.00
- ENX -0.02
- Stochastic Oscillator
- IKT 45.57
- ENX 51.02
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.